Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гемангиома инфантильная

Список литературы

  1. Léauté-Labrèze C., Harper J.I., Hoeger P.H. Infantile haemangioma // The Lancet. Lancet, 2017. Vol. 390, № 10089. P. 85–94.
  2. Darrow D.H.D.H. et al. Diagnosis and management of infantile Hemangioma // Pediatrics. Pediatrics, 2015. Vol. 136, № 4. P. e1060–e1104.
  3. Drolet B.A., Swanson E.A., Frieden I.J. Infantile Hemangiomas: An Emerging Health Issue Linked to an Increased Rate of Low Birth Weight Infants // J. Pediatr. J Pediatr, 2008. Vol. 153, № 5.
  4. Frieden I.J. et al. Infantile hemangiomas: Current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas // Pediatric Dermatology. Pediatr Dermatol, 2005. Vol. 22, № 5. P. 383–406.
  5. Haggstrom A.N. et al. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment // Pediatrics. Pediatrics, 2006. Vol. 118, № 3. P. 882–887.
  6. Léauté-Labrèze C. Hémangiomes infantiles: Actualités dans le traitement // Archives de Pediatrie. Arch Pediatr, 2013. Vol. 20, № 5. P. 517–522.
  7. Enjolras O. Angiomes // Revue du Praticien. Rev Prat, 2003. Vol. 53, № 8. P. 899–905.
  8. Stefan D. et al. Angiogénèse: de la physiologie à la therapeutique. // Réanium Urgences. 2000. Vol. 9. P. 534–544.
  9. Presta M. et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis // Cytokine Growth Factor Rev. Cytokine Growth Factor Rev, 2005. Vol. 16, № 2 SPEC. ISS. P. 159–178.
  10. Léauté-Labrèze C., Taïeb A. Efficacité des bêtabloquants dans les hémangiomes capillaires infantiles : signification physiopathologique et conséquences thérapeutiques // Ann. Dermatol. Venereol. Ann Dermatol Venereol, 2008. Vol. 135, № 12. P. 860–862.
  11. Wassef M. et al. Vascular tumours and malformations, classification, pathology and imaging // Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 51, № 4–5. P. 263–281.
  12. Drolet B.A. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference // Pediatrics. Pediatrics, 2013. Vol. 131, № 1. P. 128–140.
  13. Léauté-Labrèze C., Sans-Martin V. Infantile hemangioma // Press. Medicale. Elsevier Masson SAS, 2010. Vol. 39, № 4. P. 499–510.
  14. Enjolras O., Mulliken J.B. Vascular tumors and vascular malformations (new issues) // Adv. Dermatol. 1997. Vol. 13. P. 375–423.
  15. Wechsler J. et al. Pathologie cutanée tumorale. P. 697.
  16. Casanova D. et al. Les hémangiomes cutanés : aspects cliniques // Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 4–5, № 51. P. 287–292.
  17. Philandrianos C. et al. Diagnosis and management of vascular anomalies // Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2011. Vol. 56, № 3. P. 241–253.
  18. Bianchi A. et al. Congenital ulcerated lip hemangioma treated with a cleft lip technique // Cleft Palate-Craniofacial J. Cleft Palate Craniofac J, 2017. Vol. 54, № 2. P. 231–234.
  19. Nakayama H. CLINICAL AND HISTOLOGICAL STUDIES OF THE CLASSIFICATION AND THE NATURAL COURSE OF THE STRAWBERRY MARK // J. Dermatol. John Wiley & Sons, Ltd, 1981. Vol. 8, № 4. P. 277–291.
  20. Waner M. et al. The nonrandom distribution of facial hemangiomas // Arch. Dermatol. Arch Dermatol, 2003. Vol. 139, № 7. P. 869–875.
  21. Haggstrom A.N. et al. Risk for PHACE syndrome in infants with large facial hemangiomas // Pediatrics. Pediatrics, 2010. Vol. 126, № 2.
  22. Chiller K.G., Passaro D., Frieden I.J. Hemangiomas of infancy: Clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex // Arch. Dermatol. Arch Dermatol, 2002. Vol. 138, № 12. P. 1567–1576.
  23. Metry D.W. et al. The many faces of PHACE syndrome // J. Pediatr. J Pediatr, 2001. Vol. 139, № 1. P. 117–123.
  24. Léauté-Labrèze C., Prey S., Ezzedine K. Infantile haemangioma: Part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities // J. Eur. Acad. Dermatology Venereol. J Eur Acad Dermatol Venereol, 2011. Vol. 25, № 11. P. 1245–1253.
  25. Chang L.C. et al. Growth characteristics of infantile hemangiomas: implications for management // Pediatrics. Pediatrics, 2008. Vol. 122, № 2. P. 360–367.
  26. Baselga E. et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy // JAMA dermatology. JAMA Dermatol, 2016. Vol. 152, № 11. P. 1239–1243.
  27. Krowchuk D.P. et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas // Pediatrics. 2019. Vol. 143, № 1.
  28. Haggstrom A.N. et al. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development // Pediatrics. Pediatrics, 2006. Vol. 117, № 3. P. 698–703.
  29. Chamlin S.L. et al. Multicenter prospective study of ulcerated hemangiomas // J. Pediatr. J Pediatr, 2007. Vol. 151, № 6.
  30. Dubois J. et al. Orbit and eyelid hemangiomas: Is there a relationship between location and ocular problems? // J. Am. Acad. Dermatol. 2006. Vol. 55, № 4. P. 614–619.
  31. Holland K.E., Drolet B.A. Infantile Hemangioma // Pediatric Clinics of North America. Pediatr Clin North Am, 2010. Vol. 57, № 5. P. 1069–1083.
  32. Rahbar R. et al. The biology and management of subglottic hemangioma; past, present, future // Laryngoscope. Laryngoscope, 2004. Vol. 114, № 11. P. 1880–1891.
  33. Badi A.N. et al. Histopathologic and immunophenotypic profile of subglottic hemangioma: Multicenter study // Int. J. Pediatr. Otorhinolaryngol. Int J Pediatr Otorhinolaryngol, 2009. Vol. 73, № 9. P. 1187–1191.
  34. Christison-Lagay E.R. et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry // J. Pediatr. Surg. J Pediatr Surg, 2007. Vol. 42, № 1. P. 62–68.
  35. Levy A.D. et al. Gastrointestinal hemangiomas: Imaging findings with pathologic correlation in pediatric and adult patients // Am. J. Roentgenol. AJR Am J Roentgenol, 2001. Vol. 177, № 5. P. 1073–1081.
  36. Константинова Н.К. et al. Случай успешного лечения редкой патологии – LUMBAR синдрома // Педиатрия. 2020. Vol. 99, № 4. P. 279–282.
  37. Rotter A. et al. PHACE syndrome: clinical manifestations, diagnostic criteria, andmanagement // An. Bras. Dermatol. Sociedade Brasileira de Dermatologia, 2018. Vol. 93, № 3. P. 405.
  38. Garzon M.C. et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations // J. Pediatr. J Pediatr, 2016. Vol. 178. P. 24-33.e2.
  39. Kulungowski A.M. et al. Lessons from a liver hemangioma registry: Subtype classification // J. Pediatr. Surg. J Pediatr Surg, 2012. Vol. 47, № 1. P. 165–170.
  40. Huang S.A. et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas // N. Engl. J. Med. N Engl J Med, 2000. Vol. 343, № 3. P. 185–189.
  41. Konrad D., Ellis G., Perlman K. Spontaneous Regression of Severe Acquired Infantile Hypothyroidism Associated with Multiple Liver Hemangiomas // Pediatrics. Pediatrics, 2003. Vol. 112, № 6 I. P. 1424–1426.
  42. Bauland C.G. et al. Untreated hemangiomas: growth pattern and residual lesions // Plast. Reconstr. Surg. Plast Reconstr Surg, 2011. Vol. 127, № 4. P. 1643–1648.
  43. Maruani A. Angiomes // Pédiatre. 6e édition. 2011. P. 252–255.
  44. Iacobas I. et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring // J. Pediatr. J Pediatr, 2018. Vol. 203. P. 294-300.e2.
  45. Grant A.M. et al. Rethinking Blood Testing in Pediatric Cancer Patients: A Quality Improvement Approach // Pediatr. Qual. Saf. Wolters Kluwer Health, 2022. Vol. 7, № 3. P. e552.
  46. Babiak-Choroszczak L. et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas // Adv. Clin. Exp. Med. Adv Clin Exp Med, 2019. Vol. 28, № 3. P. 381–390.
  47. Ainipully A.M. et al. Oral Propranolol in Infantile Hemangiomas: Analysis of Factors that Affect the Outcome // J. Indian Assoc. Pediatr. Surg. Wolters Kluwer -- Medknow Publications, 2019. Vol. 24, № 3. P. 170.
  48. Sethuraman G., Yenamandra V., Gupta V. Management of infantile hemangiomas: current trends // J. Cutan. Aesthet. Surg. J Cutan Aesthet Surg, 2014. Vol. 7, № 2. P. 75.
  49. Sebaratnam D.F. et al. Infantile hemangioma. Part 2: Management // J. Am. Acad. Dermatol. J Am Acad Dermatol, 2021. Vol. 85, № 6. P. 1395–1404.
  50. Bongsebandhu-Phubhakdi C., Tempark T., Supornsilpchai V. Endocrine manifestations of PHACE syndrome // J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2019. Vol. 32, № 8. P. 797–802.
  51. Kaur K., Adamski J.J. Fecal Occult Blood Test // StatPearls. StatPearls Publishing, 2022.
  52. ElHassan N.O. et al. A Preterm Infant with Abdominal Distension and Bloody Stools // J. Pediatr. J Pediatr, 2019. Vol. 205. P. 289-289.e1.
  53. Ameen N.N. Gastrointestinal and mesenteric hemangioma; a rare case presentation // J. Sulaimani Med. Coll. 2018. Vol. 8, № 2. P. 127–129.
  54. Bourrat E. et al. PELVIS/SACRAL syndrome avec hémangiome livédoïde et bride amniotique // Ann. Dermatol. Venereol. Elsevier Masson, 2008. Vol. 135, № 12. P. 855–859.
  55. Nijmegen R. Consensus document for the treatment of infantile haemangiomas. 2017. 20 p.
  56. Elajmi A. et al. Prise en charge des anomalies vasculaires chez l’enfant // Ann. Chir. Plast. Esthétique. Elsevier Masson, 2016. Vol. 61, № 5. P. 480–497.
  57. Ding A.A. et al. Role of ultrasound in diagnosis and differential diagnosis of deep infantile hemangioma and venous malformation // J. Vasc. surgery. Venous Lymphat. Disord. J Vasc Surg Venous Lymphat Disord, 2019. Vol. 7, № 5. P. 715–723.
  58. Delmotte N. et al. Mise au point sur le traitement de l’hémangiome du nourrisson par bêta-bloquant // Therapies. Elsevier, 2012. Vol. 67, № 3. P. 257–265.
  59. Carinci S. et al. A case of congenital hypothyroidism in PHACE syndrome // J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2012. Vol. 25, № 5–6. P. 603–605.
  60. Bongsebandhu-Phubhakdi C. et al. A case of PHACE syndrome with growth hormone deficiency and abnormal thyroid functions // J. Pediatr. Endocrinol. Metab. J Pediatr Endocrinol Metab, 2019. Vol. 32, № 11.
  61. Eschard C. Hémangiomes infantiles : quand explorer et actualités thérapeutiques // Ann. Dermatol. Venereol. Elsevier Masson, 2015. Vol. 142, № 8–9. P. 476–482.
  62. Horii K.A. et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas // Pediatr. Dermatol. Pediatr Dermatol, 2011. Vol. 28, № 3. P. 245–253.
  63. Lacoste A., Léauté-Labrèze C. Formation médicale continue Clinique Hémangiomatose miliaire // Ann Dermatol Venereol. 2007. Vol. 134. P. 694–702.
  64. Canty K.M. et al. Multiple cutaneous and hepatic hemangiomas in infants // South. Med. J. South Med J, 2014. Vol. 107, № 3. P. 159–164.
  65. Luu J., Cotton C.H. Hemangioma Genetics and Associated Syndromes // Dermatol. Clin. Dermatol Clin, 2022. Vol. 40, № 4. P. 393–400.
  66. Raphael M.F. et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study // J. Am. Acad. Dermatol. J Am Acad Dermatol, 2015. Vol. 72, № 3. P. 465–472.
  67. Cushing S.L. et al. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas // Otolaryngol. Head. Neck Surg. Otolaryngol Head Neck Surg, 2011. Vol. 144, № 1. P. 78–84.
  68. Frongia G. et al. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants // World J. Pediatr. World J Pediatr, 2018. Vol. 14, № 3. P. 254–258.
  69. Zimmermann A.P. et al. Propranolol therapy for infantile haemangiomas: review of the literature // Int. J. Pediatr. Otorhinolaryngol. Int J Pediatr Otorhinolaryngol, 2010. Vol. 74, № 4. P. 338–342.
  70. Kassarjian A. et al. Infantile hepatic hemangiomas: clinical and imaging findings and their correlation with therapy // AJR. Am. J. Roentgenol. AJR Am J Roentgenol, 2004. Vol. 182, № 3. P. 785–795.
  71. Kitami M. Diffusion-weighted imaging as a routine MRI protocol for the evaluation of “infantile hemangioma” // Clin. Imaging. Clin Imaging, 2017. Vol. 46. P. 121.
  72. Park H.J. et al. Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma // PLoS One. PLoS One, 2021. Vol. 16, № 3.
  73. Шептий О.В., Круглова Л.С. Младенческая гемангиома: классификация, клиническая картина и методы коррекции // Российский журнал кожных и венерических болезней. 2016. Vol. 19, № 3. P. 178–183.
  74. Хачатрян Л.А. et al. Терапия детей с синдромом Казабаха-Мерритт // Педиатрия. 2018. Vol. 97, № 4. P. 125–134.
  75. Хачатрян Л.А., Николаева Д.М., Щербаков А.П. Когда болезнь выходит за пределы кожи – изменения на коже могут быть признаком системного заболевания // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020. Vol. 19, № 3. P. 95–104.
  76. Rodríguez Bandera A.I. et al. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment // J. Am. Acad. Dermatol. J Am Acad Dermatol, 2021. Vol. 85, № 6. P. 1379–1392.
  77. Hess C.P. et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome // AJNR. Am. J. Neuroradiol. AJNR Am J Neuroradiol, 2010. Vol. 31, № 10. P. 1980–1986.
  78. Heyer G.L. et al. The cerebral vasculopathy of PHACES syndrome // Stroke. Stroke, 2008. Vol. 39, № 2. P. 308–316.
  79. Prada F. et al. Complex Aortic Coarctation and PHACE Syndrome // Rev. Española Cardiol. (English Ed. Elsevier, 2010. Vol. 63, № 11. P. 1367–1370.
  80. Buckmiller L., Dyamenahalli U., Richter G.T. Propranolol for airway hemangiomas: case report of novel treatment // Laryngoscope. Laryngoscope, 2009. Vol. 119, № 10. P. 2051–2054.
  81. Kveton J.F., Pillsbury H.C. Conservative Treatment of Infantile Subglottic Hemangioma With Corticosteroids // Arch. Otolaryngol. American Medical Association, 1982. Vol. 108, № 2. P. 117–119.
  82. Drolet B.A. et al. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas // J. Pediatr. J Pediatr, 2012. Vol. 160, № 6.
  83. Hoornweg M.J. et al. Malignant differential diagnosis in children referred for infantile hemangioma // Ann. Plast. Surg. Ann Plast Surg, 2015. Vol. 74, № 1. P. 43–46.
  84. Хачатрян Л.А., Николаева Д.М. Современная терапия инфантильных гемангиом // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021. Vol. 20, № 2. P. 156–167.
  85. Hoeger P.H.P.H. et al. Treatment of infantile haemangiomas: recommendations of a European expert group // Eur. J. Pediatr. Eur J Pediatr, 2015. Vol. 174, № 7. P. 855–865.
  86. Marqueling A.L. et al. Propranolol and infantile hemangiomas four years later: a systematic review // Pediatr. Dermatol. Pediatr Dermatol, 2013. Vol. 30, № 2. P. 182–191.
  87. Liu X. et al. Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis // PLoS One. Public Library of Science, 2015. Vol. 10, № 9.
  88. Enjolras O. et al. [Vincristine treatment for function- and life-threatening infantile hemangioma] // Arch. Pediatr. Arch Pediatr, 2004. Vol. 11, № 2. P. 99–107.
  89. Хачатрян Л.А. et al. Новые подходы к решению старой проблемы // Вопросы гематологии / онкологии и иммунопатологии в педиатрии. 2022. Vol. 21, № 1. P. 122–135.
  90. Lie E., Püttgen K.B. Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration // Br. J. Dermatol. Br J Dermatol, 2017. Vol. 176, № 4. P. 1064–1067.
  91. Boon L.M. et al. Medical treatment of juvenile hemangiomas // Ann. Chir. Plast. Esthet. Ann Chir Plast Esthet, 2006. Vol. 51, № 4–5. P. 310–320.
  92. Breur J.M.P.J.J.M. et al. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report // Pediatr. Dermatol. Pediatr Dermatol, 2011. Vol. 28, № 2. P. 169–171.
  93. Raphaël M.F. et al. Atenolol: a promising alternative to propranolol for the treatment of hemangiomas // J. Am. Acad. Dermatol. J Am Acad Dermatol, 2011. Vol. 65, № 2. P. 420–421.
  94. Abarzúa-Araya Á. et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study // J. Am. Acad. Dermatol. J Am Acad Dermatol, 2014. Vol. 70, № 6. P. 1045–1049.
  95. Ji Y. et al. Oral atenolol therapy for proliferating infantile hemangioma: A prospective study // Medicine (Baltimore). Medicine (Baltimore), 2016. Vol. 95, № 24.
  96. De Graaf M. et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group // J. Plast. Reconstr. Aesthet. Surg. J Plast Reconstr Aesthet Surg, 2013. Vol. 66, № 12. P. 1732–1740.
  97. Püttgen K. et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas // Pediatrics. 2016. Vol. 138, № 3.
  98. Chan H. et al. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds // Pediatrics. Pediatrics, 2013. Vol. 131, № 6.
  99. Borok J. et al. Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial // Br. J. Dermatol. Br J Dermatol, 2018. Vol. 178, № 1. P. e51–e52.
  100. Hartmann F. et al. Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children // J. Eur. Acad. Dermatol. Venereol. J Eur Acad Dermatol Venereol, 2017. Vol. 31, № 8. P. 1372–1379.
  101. Zhong S.X. et al. Infantile Hemangioma: Clinical Characteristics and Efficacy of Treatment with the Long-Pulsed 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser in 794 Chinese Patients // Pediatr. Dermatol. Pediatr Dermatol, 2015. Vol. 32, № 4. P. 495–500.
  102. Chinnadurai S., Sathe N.A., Surawicz T. Laser treatment of infantile hemangioma: A systematic review // Lasers Surg. Med. Lasers Surg Med, 2016. Vol. 48, № 3. P. 221–233.
  103. Enjolras O., Picard A., Soupre V. Congenital haemangiomas and other rare infantile vascular tumours // Ann. Chir. Plast. Esthet. Elsevier Masson SAS, 2006. Vol. 51, № 4–5. P. 339–346.
  104. Berenguer B. et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features // Pediatr. Dev. Pathol. Pediatr Dev Pathol, 2003. Vol. 6, № 6. P. 495–510.
  105. North P.E. et al. Congenital nonprogressive hemangioma: a distinct clinicopathologic entity unlike infantile hemangioma // Arch. Dermatol. Arch Dermatol, 2001. Vol. 137, № 12. P. 1607–1620.
  106. Rodriguez V. et al. Kasabach-merritt phenomenon: case series and retrospective review of the mayo clinic experience // J. Pediatr. Hematol. Oncol. J Pediatr Hematol Oncol, 2009. Vol. 31, № 7. P. 522–526.
  107. Ryan C. et al. Kasabach-Merritt phenomenon: a single centre experience // Eur. J. Haematol. Eur J Haematol, 2010. Vol. 84, № 2. P. 97–104.
  108. Croteau S.E. et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals // J. Pediatr. J Pediatr, 2013. Vol. 162, № 1. P. 142–147.
  109. Satter E.K., Graham B.S., Gibbs N.F. Congenital tufted angioma // Pediatr. Dermatol. Pediatr Dermatol, 2002. Vol. 19, № 5. P. 445–447.
  110. Хачатрян Л.А., Клецкая И.С., Орехова Е.В. Синдромальная венозная мальформация – диссеминированный венозный ангиоматоз Бинаю // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019. Vol. 18, № 3. P. 78–87.
  111. Starkey E., Shahidullah H. Propranolol for infantile haemangiomas: A review // Archives of Disease in Childhood. Arch Dis Child, 2011. Vol. 96, № 9. P. 890–893.
  112. Biesbroeck L., Brandling-Bennett H.A. Propranolol for infantile haemangiomas: review of report of a consensus conference // Arch. Dis. Child. Educ. Pract. Ed. Arch Dis Child Educ Pract Ed, 2014. Vol. 99, № 3. P. 95–97.
  113. Thaivalappil S. et al. Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants With Hemangiomas // JAMA Otolaryngol. Neck Surg. American Medical Association, 2013. Vol. 139, № 10. P. 1026–1031.
  114. Greenberger S., Bischoff J. Infantile hemangioma-mechanism(s) of drug action on a vascular tumor // Cold Spring Harb. Perspect. Med. Cold Spring Harb Perspect Med, 2011. Vol. 1, № 1.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу